Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Ribociclib|DRUG: Letrozole 2.5mg|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel
Sponsor: SOLTI Breast Cancer Research Group
Collaborators: Novartis